Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Equillium
Equillium
Biotech
Equillium misses primary, key secondaries, plans approval filing
The biotech brushed off the setback, highlighting other secondary endpoints and post hoc analyses to make the case it could file for FDA approval.
Nick Paul Taylor
Mar 27, 2025 9:52am
Equillium delivers new lupus data to Ono's doorstep
Apr 1, 2024 10:53am
Equillium swaps subcutaneous cytokine inhibitor for oral option
Dec 21, 2023 10:58am
Equillium is no longer buying Metacrine, citing new cash
Dec 27, 2022 4:00pm
Equillium buys struggling Metacrine in $26M all-stock deal
Sep 7, 2022 8:45am
Equillium adds 3 drugs to pipeline via $329M Bioniz buy
Feb 16, 2022 7:00am
